James S. Welsh

Dr. James S. Welsh

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2021 in Cancer Investigation
Verified
Journal Article
Closed access
MAMona Ariamanesh
Mona Ariamanesh
PPPejman Porouhan
Pejman Porouhan
BPBabak PeyroShabany
Babak PeyroShabany
DFDanial Fazilat-Panah
Danial Fazilat-Panah
MDMansoureh Dehghani
Mansoureh Dehghani
SJSeyed Alireza Javadinia
Seyed Alireza Javadinia
To evaluate the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine in cancer patients.364 cancer patients who received two doses of vaccine were enrolled. The presence of SARS-CoV-2 an...

29 July 2021 in International Journal of Radiation Biology
Verified
Journal Article
Closed access
SJSeyed Alireza Javadinia
Seyed Alireza Javadinia
NNNooshin Nazeminezhad
Nooshin Nazeminezhad
RGRuhollah Ghahramani-Asl
Ruhollah Ghahramani-Asl
DSDavood Soroosh
Davood Soroosh
DFDanial Fazilat-Panah
Danial Fazilat-Panah
RKRachna Kapoor
Rachna Kapoor
Osteoarthritis (OA), the most common degenerative joint disease, is associated with severe functional limitation and impairment of quality of life. Numerous reports have documented the clinical eff...

11 November 2021 in Cancer Investigation
Verified
Journal Article
Closed access
SJSeyed Alireza Javadinia
Seyed Alireza Javadinia
MAMona Ariamanesh
Mona Ariamanesh
MNMaryam Nabavifard
Maryam Nabavifard
PPPejman Porouhan
Pejman Porouhan
BPBabak PeyroShabany
Babak PeyroShabany
MDMansoureh Dehghani
Mansoureh Dehghani
Patients with cancer are at significantly greater risk of COVID-19 and its complications than the general population. Since IgG antibodies remain detectable well after infection with the SARS-CoV-2 virus, seroprevalence can be used to estimate the proportion of the cancer population previously infected and potentially immune to SARS-CoV-2. The current study is a multi-center, prospective observational study to assess the seroprevalence of SARS-CoV-2 IgG antibody in a cancer population referred for vaccination between April and June 2021. Of a total of 270 adult patients with cancer accrued, 16% reported a history of COVID-19 more than four weeks previously confirmed by PCR. At the same time, serologic positivity for SARSCoV2 IgG was found in 29% of patients prior to vaccination including nearly 20% of patients without a history of confirmed COVID-19. Seropositivity was significantly greater in females consistent with higher rates in patients with breast cancer and gynecologic cancers. A seroconversion rate of 79.5% was observed in cancer patients with a history of PCR confirmed COVID-19, less than observed in the general population. In multivariable analysis, gender and prior history of COVID-19 were both independently associated with seropositivity prior to vaccination. Follow-up is continuing of this cohort of patients with cancer following vaccination to assess antibody and clinical outcomes.

19 March 2019 in Journal of Radiation Oncology
Verified
Journal Article
Closed access
PDF file
CMChelsea Miller
Chelsea Miller
BABasel Altoos
Basel Altoos
EDEthan A. DeJongh
Ethan A. DeJongh
MPMark Pankuch
Mark Pankuch
DDDon F. DeJongh
Don F. DeJongh
JWJames S. Welsh
James S. Welsh

25 May 2019 in Journal of Radiation Oncology
Verified
Journal Article
Closed access
PDF file
COCaesar E. Ordoñez
Caesar E. Ordoñez
NKNicholas T. Karonis
Nicholas T. Karonis
KDKirk L. Duffin
Kirk L. Duffin
JWJohn R. Winans
John R. Winans
EDEthan A. DeJongh
Ethan A. DeJongh
JWJames S. Welsh
James S. Welsh

1 August 2010 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
CPChristopher S. Platta
Christopher S. Platta
CMChristopher MacKay
Christopher MacKay
JWJames S. Welsh
James S. Welsh
Pituitary adenomas comprise approximately 10% to 20% of all central nervous system neoplasms whereas autopsy series have suggested that the incidence of pituitary adenoma in the general population may approach 25%. Several treatment modalities are used in the treatment of pituitary adenomas, including observation, surgery, medical intervention, and radiotherapy. The treatment modality employed depends greatly on the type of pituitary adenoma and presenting symptoms. This review will discuss the biology of pituitary adenomas and the current management principles for the treatment of prolactinomas, Cushing disease, acromegaly, and nonsecretory adenomas, with an emphasis on the published radiotherapeutic literature.